128 related articles for article (PubMed ID: 17292918)
1. The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain.
Walter M; Lucet IS; Patel O; Broughton SE; Bamert R; Williams NK; Fantino E; Wilks AF; Rossjohn J
J Mol Biol; 2007 Mar; 367(3):839-47. PubMed ID: 17292918
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
Foster R; Griffith R; Ferrao P; Ashman L
J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
[TBL] [Abstract][Full Text] [Related]
3. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
[TBL] [Abstract][Full Text] [Related]
4. Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Wodicka LM; Ciceri P; Davis MI; Hunt JP; Floyd M; Salerno S; Hua XH; Ford JM; Armstrong RC; Zarrinkar PP; Treiber DK
Chem Biol; 2010 Nov; 17(11):1241-9. PubMed ID: 21095574
[TBL] [Abstract][Full Text] [Related]
5. FMIP, a novel Fms-interacting protein, affects granulocyte/macrophage differentiation.
Tamura T; Mancini A; Joos H; Koch A; Hakim C; Dumanski J; Weidner KM; Niemann H
Oncogene; 1999 Nov; 18(47):6488-95. PubMed ID: 10597251
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
Mol CD; Dougan DR; Schneider TR; Skene RJ; Kraus ML; Scheibe DN; Snell GP; Zou H; Sang BC; Wilson KP
J Biol Chem; 2004 Jul; 279(30):31655-63. PubMed ID: 15123710
[TBL] [Abstract][Full Text] [Related]
7. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T
Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018
[TBL] [Abstract][Full Text] [Related]
8. Structure-function studies on human macrophage colony-stimulating factor (M-CSF).
Koths K
Mol Reprod Dev; 1997 Jan; 46(1):31-7; discussion 37-8. PubMed ID: 8981361
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a new potent bisamide FMS kinase inhibitor.
El-Gamal MI; Jung MH; Oh CH
Bioorg Med Chem Lett; 2010 Jun; 20(11):3216-8. PubMed ID: 20457522
[TBL] [Abstract][Full Text] [Related]
10. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
Ali S; Ali S
Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
[TBL] [Abstract][Full Text] [Related]
11. Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots.
Savvides SN; Boone T; Andrew Karplus P
Nat Struct Biol; 2000 Jun; 7(6):486-91. PubMed ID: 10881197
[TBL] [Abstract][Full Text] [Related]
12. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.
Zou J; Wang YD; Ma FX; Xiang ML; Shi B; Wei YQ; Yang SY
Proteins; 2008 Jul; 72(1):323-32. PubMed ID: 18214972
[TBL] [Abstract][Full Text] [Related]
13. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
14. The M-CSF receptor substrate and interacting protein FMIP is governed in its subcellular localization by protein kinase C-mediated phosphorylation, and thereby potentiates M-CSF-mediated differentiation.
Mancini A; Koch A; Whetton AD; Tamura T
Oncogene; 2004 Aug; 23(39):6581-9. PubMed ID: 15221008
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors.
Schubert C; Schalk-Hihi C; Struble GT; Ma HC; Petrounia IP; Brandt B; Deckman IC; Patch RJ; Player MR; Spurlino JC; Springer BA
J Biol Chem; 2007 Feb; 282(6):4094-101. PubMed ID: 17132624
[TBL] [Abstract][Full Text] [Related]
16. Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor.
Hake MJ; Choowongkomon K; Kostenko O; Carlin CR; Sönnichsen FD
Biochemistry; 2008 Mar; 47(10):3096-108. PubMed ID: 18269246
[TBL] [Abstract][Full Text] [Related]
17. Structure of human Fyn kinase domain complexed with staurosporine.
Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
[TBL] [Abstract][Full Text] [Related]
18. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
[TBL] [Abstract][Full Text] [Related]
19. Crystallographic structure of the SH3 domain of the human c-Yes tyrosine kinase: loop flexibility and amyloid aggregation.
Martín-García JM; Luque I; Mateo PL; Ruiz-Sanz J; Cámara-Artigas A
FEBS Lett; 2007 May; 581(9):1701-6. PubMed ID: 17418139
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for compound C inhibition of the human AMP-activated protein kinase α2 subunit kinase domain.
Handa N; Takagi T; Saijo S; Kishishita S; Takaya D; Toyama M; Terada T; Shirouzu M; Suzuki A; Lee S; Yamauchi T; Okada-Iwabu M; Iwabu M; Kadowaki T; Minokoshi Y; Yokoyama S
Acta Crystallogr D Biol Crystallogr; 2011 May; 67(Pt 5):480-7. PubMed ID: 21543851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
